Onconetix, Inc. Files 8-K Reporting Event
Ticker: ONCO · Form: 8-K · Filed: Apr 8, 2024 · CIK: 1782107
Sentiment: neutral
Topics: 8-K, corporate-event
Related Tickers: ONCO
TL;DR
Onconetix (ONCO) filed an 8-K on 3/27. Details TBD.
AI Summary
Onconetix, Inc. filed an 8-K on April 8, 2024, reporting an event that occurred on March 27, 2024. The filing indicates a change in the company's status or operations, though specific details of the event are not provided in this excerpt. The company, formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc., is incorporated in Delaware and headquartered in Cincinnati, Ohio.
Why It Matters
This 8-K filing signals a material event for Onconetix, Inc., requiring disclosure to investors and the public. The nature of the event could impact the company's business, strategy, or financial standing.
Risk Assessment
Risk Level: medium — The filing of an 8-K often indicates significant corporate events, which can introduce uncertainty and risk for investors until more details are disclosed.
Key Players & Entities
- Onconetix, Inc. (company) — Registrant
- Blue Water Biotech, Inc. (company) — Former company name
- Blue Water Vaccines Inc. (company) — Former company name
- March 27, 2024 (date) — Earliest event date
- April 8, 2024 (date) — Filing date
- 513-620-4101 (phone_number) — Registrant's telephone number
FAQ
What specific event occurred on March 27, 2024, that Onconetix, Inc. is reporting?
The provided excerpt does not specify the nature of the event that occurred on March 27, 2024.
When did Onconetix, Inc. change its name from Blue Water Biotech, Inc.?
The date of the name change from Blue Water Biotech, Inc. was April 24, 2023.
What is the principal executive office address for Onconetix, Inc.?
The principal executive offices are located at 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202.
What is the Commission File Number for Onconetix, Inc.?
The Commission File Number for Onconetix, Inc. is 001-41294.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 811 words · 3 min read · ~3 pages · Grade level 15.2 · Accepted 2024-04-08 16:05:21
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share ONCO The Nasdaq Stock Mar
- $1.00 — the " Common Stock "), had closed below $1.00 per share for 30 consecutive business d
Filing Documents
- ea0203476-8k_onconetix.htm (8-K) — 25KB
- 0001213900-24-031167.txt ( ) — 196KB
- onco-20240327.xsd (EX-101.SCH) — 3KB
- onco-20240327_lab.xml (EX-101.LAB) — 33KB
- onco-20240327_pre.xml (EX-101.PRE) — 22KB
- ea0203476-8k_onconetix_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events As previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission on September 22, 2023, Onconetix, Inc., a Delaware corporation (the " Company ") received a written notice (the " Notice ") from the Listing Qualifications Department (the " Staff ") of The Nasdaq Stock Market LLC (" Nasdaq ") indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) which sets forth the minimum bid price requirement for continued listing on the Nasdaq Capital Market (the " Minimum Bid Requirement ") as the bid price of the Company's common stock, par value $0.00001 per share (the " Common Stock "), had closed below $1.00 per share for 30 consecutive business days. The Notice stated that the Company had 180 calendar days, or until March 16, 2024, to regain compliance with the Minimum Bid Requirement. The Notice also stated that the Company may be eligible for an additional 180-calendar day compliance period so long as it satisfies the criteria for initial listing on the Nasdaq Capital Market, except the Minimum Bid Requirement, and the continued listing requirement for market value of publicly held shares, and the Company provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. On March 13, 2024, the Company submitted a plan of compliance to Nasdaq setting forth its plans to evidence compliance with the Minimum Bid Requirement, which include potentially effecting a reverse stock split. On March 27, 2024, the Company received a written notice from the Staff of Nasdaq informing the Company that it has received an additional 180-day period, or until September 16, 2024, to regain compliance with the Minimum Bid Requirement. If the Company does not regain compliance with the Minimum Bid Requirement by September 16, 2024, the Staff will provide written notice to the Company that the Common Stock
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 8, 2024 ONCONETIX, INC. By: /s/ Bruce Harmon Bruce Harmon Chief Financial Officer 2